| James Carlton Hardwick Iii, MD | |
|
4215 15th St, Gulfport, MS 39501 | |
| (228) 863-5211 | |
| (228) 863-4101 |
| Full Name | James Carlton Hardwick Iii |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 29 Years |
| Location | 4215 15th St, Gulfport, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437130911 | NPI | - | NPPES |
| 1575534 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 17874 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Hospital At Gulfport | Gulfport, MS | Hospital |
| Merit Health Biloxi | Biloxi, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Memorial Hospital At Gulfport | 2466524012 | 376 |
News Archive
WHO urges affected countries to scale up their investment in tackling 17 neglected tropical diseases in order to improve the health and well-being of more than 1.5 billion people. This investment would represent as little as 0.1% of current domestic expenditure on health in affected low and middle income countries for the period 2015-2030.
The University of Michigan Health System will participate in the Pioneer Accountable Care Organization (ACO) model, in partnership with IHA Health Services Corporation, an Ann Arbor, Mich.-based multi-specialty group practice.
Cancer Research UK scientists have identified an important new protein target which could be used to produce highly focused vaccine therapies for cancer - according to research published in the Journal of Clinical Investigation.
Hemispherx Biopharma, Inc., announced that it has received a report, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease, that summarizes the results of a three year Japanese government funded program to develop and test a nasally delivered H5N1 (Avian Flu) vaccine which, when coupled with Ampligen®, an experimental therapeutic, provided a robust and long lasting immune response to the vaccine.
Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced that interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) were presented by Jorge Cortes, M.D. and discussed at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) by Farhad Ravandi, M.D., who presided over the ASCO discussion session, both of the University of Texas M.D. Anderson Cancer Center.
› Verified 9 days ago
| Entity Name | Memorial Hospital At Gulfport |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215546635 PECOS PAC ID: 2466524012 Enrollment ID: O20090515000396 |
News Archive
WHO urges affected countries to scale up their investment in tackling 17 neglected tropical diseases in order to improve the health and well-being of more than 1.5 billion people. This investment would represent as little as 0.1% of current domestic expenditure on health in affected low and middle income countries for the period 2015-2030.
The University of Michigan Health System will participate in the Pioneer Accountable Care Organization (ACO) model, in partnership with IHA Health Services Corporation, an Ann Arbor, Mich.-based multi-specialty group practice.
Cancer Research UK scientists have identified an important new protein target which could be used to produce highly focused vaccine therapies for cancer - according to research published in the Journal of Clinical Investigation.
Hemispherx Biopharma, Inc., announced that it has received a report, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease, that summarizes the results of a three year Japanese government funded program to develop and test a nasally delivered H5N1 (Avian Flu) vaccine which, when coupled with Ampligen®, an experimental therapeutic, provided a robust and long lasting immune response to the vaccine.
Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced that interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) were presented by Jorge Cortes, M.D. and discussed at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) by Farhad Ravandi, M.D., who presided over the ASCO discussion session, both of the University of Texas M.D. Anderson Cancer Center.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Carlton Hardwick Iii, MD Po Box 1810, Gulfport, MS 39502 Ph: (228) 575-1194 | James Carlton Hardwick Iii, MD 4215 15th St, Gulfport, MS 39501 Ph: (228) 863-5211 |
News Archive
WHO urges affected countries to scale up their investment in tackling 17 neglected tropical diseases in order to improve the health and well-being of more than 1.5 billion people. This investment would represent as little as 0.1% of current domestic expenditure on health in affected low and middle income countries for the period 2015-2030.
The University of Michigan Health System will participate in the Pioneer Accountable Care Organization (ACO) model, in partnership with IHA Health Services Corporation, an Ann Arbor, Mich.-based multi-specialty group practice.
Cancer Research UK scientists have identified an important new protein target which could be used to produce highly focused vaccine therapies for cancer - according to research published in the Journal of Clinical Investigation.
Hemispherx Biopharma, Inc., announced that it has received a report, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease, that summarizes the results of a three year Japanese government funded program to develop and test a nasally delivered H5N1 (Avian Flu) vaccine which, when coupled with Ampligen®, an experimental therapeutic, provided a robust and long lasting immune response to the vaccine.
Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced that interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) were presented by Jorge Cortes, M.D. and discussed at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) by Farhad Ravandi, M.D., who presided over the ASCO discussion session, both of the University of Texas M.D. Anderson Cancer Center.
› Verified 9 days ago
Dr. Nabil Azar, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1340 Broad Ave, Suite 310, Gulfport, MS 39501 Phone: 228-575-1400 Fax: 228-575-1414 | |
Dr. Fahad Javed, M.D., Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4215 15th St, Gulfport, MS 39501 Phone: 228-863-5211 Fax: 228-863-4101 | |
Indrajit J Patel, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4500 13th St, Gulfport, MS 39501 Phone: 228-867-5201 Fax: 228-867-3152 | |
Dr. Thomas Blanks, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1110 Broad Ave, Suite 700, Gulfport, MS 39501 Phone: 228-864-0314 Fax: 228-864-0425 | |
Dr. Stephanie Fussell, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1340 Broad Ave Ste 330, Gulfport, MS 39501 Phone: 228-575-1234 Fax: 228-867-4828 | |
Dr. Malcolm Scott Dean, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4500 13th St, Gulfport, MS 39501 Phone: 228-867-5201 Fax: 228-867-3152 | |
Matthew Jacob Murray, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12330 Ashley Dr, Gulfport, MS 39503 Phone: 228-831-1572 Fax: 228-831-1218 |